Smart polymer for antibody purification

涉及人单克隆抗体的治疗策略正变得越来越普遍。因此，降低这些药物成本的愿望正在施加相当大的压力，以使制造过程更有效和更具成本效益。然而，虽然生产抗体的细胞培养技术已经改进到产量大于5 g/L，但从培养基中纯化抗体已成为主要的工艺瓶颈。目前，利用层析柱选择性地从细胞培养基中捕获抗体是纯化抗体最有效的方法。不幸的是，现有的色谱柱非常昂贵，需要严格的清洗/再生过程才能重复使用，并且由于固定在固体支撑上，通常以低于化学计量量的量结合目标。为了解决这些缺点，BioAstra技术公司和INRS将开发一种可回收的清除剂，可以从细胞培养基中捕获和回收单克隆抗体，从而绕过色谱的需要。该项目是培训该地区HQP的绝佳机会，具有重要的社会和经济意义。该项目的产出将构成一项重大的技术进步，将降低单克隆抗体及其相应治疗的成本。

Therapeutic strategies involving human monoclonal antibodies are becoming increasingly prevalent. Thus, the desire to reduce the cost of these drugs is exerting considerable pressure to make the manufacturing process more efficient and cost effective. However, while cell-culturing technology to produce antibodies has improved to deliver yields greater than 5 g/L, purification of the antibody from the medium has become a major process bottleneck. Currently, the use of chromatography columns that selectively capture antibodies from cell culture medium is the most effective method for purifying antibodies. Unfortunately, existing columns are extremely expensive, require harsh cleaning/regeneration processes in order to be reused, and often bind the target in a less-than-stoichiometric amount due to its immobilization on a solid support. To address these shortcomings, BioAstra Technologies Inc. and INRS will develop a recyclable scavenger that can capture and retrieve monoclonal antibodies from cell culture medium, thereby bypassing the need for chromatography. This project represents an excellent opportunity to train HQP in this area, which is of great social and economic importance. The output of this project will constitute a major technological advance that will reduce the cost of monoclonal antibodies and their corresponding therapies.